Search

Many threatened species require ongoing management, which is often funded through short project cycles. Evaluating whether the management is effective in protecting a species is important to inform future management investments. For migratory species, management may affect only part of a species' annual cycle, and reversing a population decline is challenging to achieve and demonstrate. Here, we evaluate whether conservation management projects funded by the European LIFE programme to safeguard a migratory vulture population achieved their major objective of stabilizing the target breeding population. Between 2012 and 2022, an international alliance of conservation organizations implemented multiple actions to reduce poisoning, direct persecution, and electrocution and collision with power lines along the Eastern Mediterranean flyway. We monitored breeding territories of the Balkan population of the globally endangered Egyptian Vulture Neophron percnopterus between 2006 and 2022, and tracked 60 young birds with GPS transmitters since 2010. We used these data to examine whether population growth rate and survival probability had increased since project implementation. The mean annual survival probability of adult territorial birds increased by 1.9% since 2014 from 0.937 to 0.955, and the monthly survival probability of wild juvenile birds increased by 9.7% from 0.833 to 0.914 since 2018. The population growth rate across the Balkans increased by 6.9% from 0.939 before 2018 to 1.005 since 2018. This indicates that the Egyptian Vulture population has remained stable for the past 5 years (2018–2022), but at a population size that is only half (105 adult territorial birds in 2022) than at the beginning of the time series (204 in 2006). We caution that ongoing management along the flyway and reinforcement are required to ensure that the Egyptian Vulture population on the Balkans can recover, but we show that flyway‐scale collaboration of direct conservation actions can have lasting benefits for migratory species. [ABSTRACT FROM AUTHOR]

In the present paper we continue the project of systematic construction of invariant differential operators on the example of the non-compact algebra s o ∗ (10) . We use the maximal Heisenberg parabolic subalgebra P = M ⊕ A ⊕ N with M = s u (3 , 1) ⊕ s u (2) ≅ s o ∗ (6) ⊕ s o (3) . We give the main and the reduced multiplets of indecomposable elementary representations. This includes the explicit parametrization of the intertwining differential operators between the ERS. Due to the recently established parabolic relations the multiplet classification results are valid also for the algebras s o (p , q) (with p + q = 10 , p ≥ q ≥ 2 ) with maximal Heisenberg parabolic subalgebra: P ′ = M ′ ⊕ A ′ ⊕ N ′ , M ′ = s o (p − 2 , q − 2) ⊕ s l (2 , I R) , M ′ C ≅ M C . [ABSTRACT FROM AUTHOR]

In this paper, we construct explicitly the intertwining differential operators for the Jacobi algebra 2 . For the construction, we use the singular vectors of the Verma modules over 2 which we have constructed earlier. We construct the function spaces on which the operators act. We find two versions of the left (representation) action and the right action. These actions are combined with the singular vectors to provide the intertwining differential operators. [ABSTRACT FROM AUTHOR]

Raynaud's syndrome is characterized by paroxysmal vasospasm in the digital arterioles, following exposure to cold or stress. Pain, swelling, stiffness, and hypoesthesia are observed as manifestations. The presence of a trophic ulcer is accompanied by a range of severe manifestations. The assaults occur in three distinct phases, namely vasospastic, plethoric, and erythema. Various approaches improve the overall well-being of a patient. It is possible to differentiate between primary and secondary Raynaud's syndrome, the latter being linked to systemic diseases. The application of botulin toxin is commonly indicated in several medical conditions including focal dystonia, spasticity with or without contractures, paraparesis in children with cerebral palsy, multiple sclerosis, brain injuries, involuntary muscle hyperactivity of a non-dystonic nature, pain management, strabismus, nystagmus, sialorrhea, and esthetic medicine. When treating Raynaud's a technique is used with injection at the base of each finger, from the palmar side, which helps with cooling and minimizing discomfort for patients. We present a clinical case of a 70-year-old female patient with Raynaud's syndrome in which we have placed 70E distributed to both hands botulin toxin type A. Improvement in the patient's symptomatology was noticed on day 3, with warming of the hands, lack of swelling, and pain with duration of the effect little over three months. The patient underwent a six-month follow-up following the therapy with botulinum toxin type A, and no indications of recurrence or advancement of Raynaud's syndrome (RS) were seen., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2024, Penchev et al.)